Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2026)
Aclaris Therapeutics' (ACRS) quarterly EBITDA Margin came in at 1111.82% in Q1 2026, up 13106.0% year-on-year from N/an in Q1 2025, and up 36.67% quarter-over-quarter from 1755.52% in Q4 2025.
Aclaris Therapeutics (ACRS) EBITDA Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' EBITDA Margin history runs 10 years deep, the most recent figure standing at 1111.82% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 13106.0% year-over-year to 1111.82% in Q1 2026; TTM through Mar 2026 was 961.91%, a 16832.0% decrease from a year earlier, with the FY2025 full-year figure at 975.91%, down 21773.0% from the prior year.
- EBITDA Margin grew to 1111.82% in Q1 2026 per ACRS's latest filing, from 1755.52% in the prior quarter.
- Across five years, EBITDA Margin topped out at 23.03% in Q4 2023 and bottomed at 1755.52% in Q4 2025.
- The 5-year median for EBITDA Margin is 1035.9% (2025), against an average of 861.89%.
- Biggest YoY gain for EBITDA Margin was 123753 bps in 2024; the steepest drop was 105910 bps in 2024.
- Year by year, EBITDA Margin stood at 375.07% in 2022, then surged by 94 bps to 23.03% in 2023, then tumbled by 4598 bps to 1082.13% in 2024, then plunged by 62 bps to 1755.52% in 2025, then surged by 37 bps to 1111.82% in 2026.
- Per Business Quant, the three latest ACRS EBITDA Margin figures stand at 1111.82% (Q1 2026), 1755.52% (Q4 2025), and 519.82% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | -1,111.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,111.82% |
| Dec 31, 2025 | -1,755.52% |
| Sep 30, 2025 | -519.82% |
| Jun 30, 2025 | -1,035.90% |
| Mar 31, 2025 | -1,242.89% |
| Dec 31, 2024 | -1,082.13% |
| Sep 30, 2024 | -240.93% |
| Jun 30, 2024 | -464.71% |
| Mar 31, 2024 | -789.45% |
| Dec 31, 2023 | -23.03% |
| Sep 30, 2023 | -340.20% |
| Jun 30, 2023 | -1,702.25% |
| Mar 31, 2023 | -1,183.47% |
| Dec 31, 2022 | -375.07% |
| Sep 30, 2022 | -109.76% |
| Jun 30, 2022 | -1,373.95% |
| Mar 31, 2022 | -1,301.24% |
| Dec 31, 2021 | -1,525.18% |
| Sep 30, 2021 | -1,223.33% |
| Jun 30, 2021 | -987.17% |